NCT02015871View on ClinicalTrials.gov

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Trial Locations (1)

Unknown

Peking University People's Hospital (there may be multiple sites in this country), Beijing

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY